35
Participants
Start Date
October 1, 2021
Primary Completion Date
November 30, 2025
Study Completion Date
May 31, 2026
α-lactalbumin vaccine
"α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1e: 10 mcg~D1f: 20 mcg~D1g: 20 mcg (D1g will only be utilized if D1c is deemed too toxic)"
Zymosan
"Adjuvant used in vaccine preparation~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 10 mcg~DL3: 10 mcg~D1b: 10 mcg~D1e: 20 mcg~D1f: 20 mcg~D1g: 1o mcg (D1g will only be utilized if D1c is deemed too toxic)"
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland
Collaborators (1)
United States Department of Defense
FED
Anixa Biosciences, Inc.
UNKNOWN
George T. Budd
OTHER